Svante Joelson

Patient Safety Expert at AstraZeneca R&D

Location: Vastra Gotaland County, Sweden
Industry: Farmakologibranschen

Som medlem i LinkedIn kan du dela kontakter, idéer och möjligheter med 225 miljoner andra yrkespersoner.

Se dina och Svante Joelsons gemensamma kontakter.
Bli presenterad för Svante Joelson.
Kontakta Svante Joelson direkt.

Se hela Svantes profil

Svante Joelsons översikt

Nuvarande

Patient Safety Expert på AstraZeneca R&D

Utbildning

Lund University
University of Gothenburg
Västerviks Gymnasium

Kontakter

58 kontakter

Some achievements:

Defined, produced and analyzed the integrated safety information in >50 regulatory applications (NDAs/MAAs/JNDAs) for CV and GI products.

Managed several critical drug safety issues/risk management strategies.

Defined and developed e.g. computerized systems for life-cycle management of drug safety data from clinical trials with, and real world use of, the products.

A selection of publications is given below.

Patient Safety Expert

AstraZeneca R&D

Public Company; 10,001+ employees; Farmakologibranschen industry

May 1985 – Present (28 years 2 months) Mölndal, Sweden

Similar role in different organizations within Astra/AstraZeneca.
Although with experience mainly from late stage development phases and marketed product safety management, also from a number of early development projects with definition of collection, analysis and reporting of safety data with focus on the needs during the development phases, for regulatory applications and for the product’s life on the market.

Primary area of interest has been, and is, the understanding of the nature and origin of drug safety data in relation to opportunities and limitations in the analysis.

Safety Experience from Long-Term Treatment with Omeprazole
- Digestion
- 1992
Authors: Svante Joelson, I-B Joelson, P Lundborg, A Walan, M-A Wallander
Geographical Variation in Adverse Event Reporting Rates in Clinical Trials
- Pharmacoepidemiology and Drug Safety
- 1997
Authors: Svante Joelson, I-B Joelson, M-A Wallander
Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials.
- Drug Safety
- 2008
Authors: Svante Joelson, Estborn L
Incidence of urinary tract infection in patients with type 2 diabetes. Experience from adverse event reporting in clinical trials
- Pharmacoepidemiology and Drug Safety
- 2010
Authors: Svante Joelson, Hammar N, Farahmand B, Gran M, Andersson SW